Anti-CD25 targeted killing of bicistronically transduced cells: A novel safety mechanism against retroviral genotoxicity

Molecular Therapy

Volumn 15, Issue 6, 2007, Pages 1174-1181

  Ramsubir, Shobha ^a   Yoshimitsu, Makoto ^b   Medin, Jeffrey A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TAC; RETROVIRUS VECTOR; SAPORIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; FABRY DISEASE; GENE CASSETTE; GENOTOXICITY; INTRON; LIVER; MOUSE; MYELOID LEUKEMIA; NONHUMAN; SPLEEN; SURVIVAL TIME; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

3T3 CELLS; ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FABRY DISEASE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LENTIVIRUS; LEUKEMIA; MICE; MICE, INBRED C57BL; RETROVIRIDAE;

MURINAE; MUS;

EID: 34249300506     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300147     Document Type: Article

References (50)

1. Aiuti, A, Slavin, S, Aker, M, Ficara, F, Deola, S, Mortellaro, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
2. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
3. Robbins, PD and Ghivizzani, SC (1998). Viral vectors for gene therapy. Pharmacol Ther 80: 35-47.
4. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt M, McCormack MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
5. McCormack, MP and Rabbitts, TH (2004). Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 350: 913-922.
6. Baum, C, von Kalle, C, Staal, FJ, Li, Z, Fehse, B, Schmidt, M et al. (2004). Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9: 5-13.
7. Brady, RO, Gal, AE, Bradley, RM, Martensson, E, Warshaw, AL and Laster, L (1967). Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167.
8. Kase, R, Shimmoto, M, Itoh, K, Utsumi, K, Kotani, M, Taya, C et al. (1998). Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. Biochim Biophys Acta 1406: 260-266.
9. Medin, JA, Tudor, M, Simovitch, R, Quirk JM, Jacobson, S, Murray, GJ et al. (1996). Correction in trans for Fabry disease: Expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 93: 7917-7922.
10. Takenaka, T, Murray, GJ, Qin, G, Quirk JM, Ohshima, T, Qasba, P et al. (2000). Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc Natl Acad Sci USA 97: 7515-7520.
11. Yoshimitsu, M, Higuchi, K, Ramsubir, S, Nonaka, T, Rasaiah, VI, Siatskas, C et al. (2007). Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/ progenitor cells. Gene Ther 14: 256-265.
12. Yoshimitsu, M, Sato, T, Tao, K, Walia, JS, Rasaiah, VI, Sleep, GT et al. (2004). Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101: 16909-16914.
13. Qin, G, Takenaka, T, Telsch, K, Kelley, L, Howard, T, Levade, T et al. (2001). Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98: 3428-3433.
14. Taniguchi, T and Minami, Y (1993). The IL-2/IL-2 receptor system: A current overview. Cell 73: 5-8.
15. Gaffen, SL (2001). Signaling domains of the interleukin 2 receptor. Cytokine 14: 63-77.
16. Hanisch, UK and Quirion, R (1995). Interleukin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 21: 246-284.
17. David, D, Bani, L, Moreau, JL, Demaison, C, Sun, K, Salvucci, O et al. (1998). Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood 91: 165-172.
18. Rubin, LA, Kurman, CC, Fritz, ME, Biddison, WE, Boutin, B, Yarchoan, R et al. (1985). Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177.
19. Uchiyama, T, Broder, S and Waldmann, TA (1981). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126: 1393-1397.
20. Lappi, DA, Esch, FS, Barbieri, L, Stirpe, F and Soria, M (1985). Characterization of a Saponaria officinalis seed ribosome-inactivating protein: Immunoreactivity and sequence homologies. Biochem Biophys Res Commun 129: 934-942.
21. Barbieri, L, Valbonesi, P, Bonora, E, Gorini, P, Bolognesi, A and Stirpe, F (1997). Polynucleotide:aDenosine glycosidase activity of ribosome-inactivating proteins: Effect on DNA, RNA and poly(A). Nucleic Acids Res 25: 518-522.
22. Zhang, Z, Zhang, M, Garmestani, K, Talanov, VS, Plascjak PS, Beck B et al. (2006). Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 108: 1007-1012.
23. Perez-Encinas, M, Villamayor, M, Campos, A, Gonzalez, S and Bello, JL (1998). Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma. Haematologica 83: 752-754.
24. Boelens, JJ (2006). Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis 29: 413-420.
25. Futerman, AH and van Meer, G (2004). The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5: 554-565.
26. Dillman, RO (2001). Monoclonal antibody therapy for lymphoma: An update. Cancer Pract 9: 71-80.
27. Gokbuget, N and Hoelzer, D (2004). Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects. Ann Hematol 83: 201-205.
28. McLaughlin, P, Grillo-Lopez, AJ, Link, BK, Levy, R, Czuczman, MS, Williams, ME et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
29. Grillo-Lopez, AJ, Hedrick E, Rashford, M and Benyunes, M (2002). Rituximab: Ongoing and future clinical development. Semin Oncol 29: 105-112.
30. Cvetkovic, RS and Perry, CM (2006). Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66: 791-820.
31. Introna, M, Barbui, AM, Bambacioni, F, Casati, C, Gaipa, G, Borleri, G et al. (2000). Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 11: 611-620.
32. van Meerten, T, Claessen, MJ, Hagenbeek, A and Ebeling, SB (2006). The CD20/alphaCD20 'suicide' system: Novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 13: 789-797.
33. Serafini, M, Manganini, M, Borleri, G, Bonamino, M, Imberti, L, Biondi, A et al. (2004). Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther 15: 63-76.
34. Kreitman, RJ, Wilson, WH, White, JD, Stetler-Stevenson, M, Jaffe, ES, Giardina, S et al. (2000). Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622-1636.
35. Kreitman, RJ, Wilson, WH, Robbins, D, Margulies, I, Stetler-Stevenson, M, Waldmann, TA et al. (1999). Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94: 3340-3348.
36. Lin, M, Ming, A and Zhao, M (2006). Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: A clinical study. Clin Transplant 20: 325-329.
37. Chen, HR, Ji, SQ, Wang, HX, Yan, HM, Zhu, L, Liu, J et al. (2003). Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GvHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 31: 1019-1025.
38. Fecci, PE, Sweeney, AE, Grossi, PM, Nair, SK, Learn, CA Mitchell, DA et al. (2006). Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 12: 4294-4305.
39. Knutson, KL, Dang, Y, Lu, H, Lukas, J, Almand, B, Gad, E et al. (2006). IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177: 84-91.
40. Onizuka, S, Tawara, I, Shimizu, J, Sakaguchi, S, Fujita, T and Nakayama, E (1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133.
41. Zhang, M, Zhang, Z, Goldman, CK, Janik, J and Waldmann, TA (2005). Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 105: 1231-1236.
42. Jaeger, G, Neumeister, P, Brezinschek, R, Hofler, G, Quehenberger, F, Linkesch, W et al. (2002). Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: A phase II study. Eur J Haematol 69 21-26.
43. Claviez, A, Eckert, C, Seeger, K, Schrauder, A, Schrappe, M, Henze, G et al. (2006). Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica 91: 272-273.
44. Montini, E, Cesana, D, Schmidt M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity, of lentiviral vector integration. Nat Biotechnol 24: 687-696.
45. De Palma, M, Montini, E, Santoni de Sio, FR, Benedicenti, F, Gentile, A, Medico, E et al. (2005). Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105: 2307-2315.
46. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
47. Silvertown, JD, Walia, JS and Medin, JA (2005). Cloning, sequencing and characterization of lentiviral-mediated expression of rhesus macaque (Macaca mulatta) interleukin-2 receptor alpha cDNA. Dev Comp Immunol 29: 989-1002.
48. Naldini, L, Blamer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
49. Medin, JA, Brandt JE, Rozler, E, Nelson, M, Bartholomew, A, Li, C et al. (1999). Ex vivo expansion and genetic marking of primitive human and baboon hernatopoietic cells. Ann NY Acad Sci 872: 233-240; discussion 240-242.
50. Ohshima, T, Murray, GJ, Swaim, WD, Longenecker, G, Quirk, JM, Cardarelli, CO et al. (1997). alpha-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA 94: 2540-2544.